Patients with a diagnosis of acute deep venous thrombosis have traditionally been hospitalized and treated with unfractionated heparin followed by oral anticoagulation therapy. Several clinical trials have shown that low-molecular-weight heparin is at least as safe and effective as unfractionated heparin in the treatment of uncomplicated deep venous thrombosis. The use of low-molecular-weight h...

background: the objective of this study is to optimize the effective dose of heparin and ligustrazine hydrochloride injection (lhi) for drug combination. materials and methods: the animal clinical study of lhi was performed by the rat’s model of induced arteriovenous shunt thrombosis. experimental animals were grouped into several groups and separately treated with both lhi (20, 40, 80 mg/kg, i...

BACKGROUND The safety and efficacy of taking low-molecular-weight heparin at home was previously demonstrated in a clinical trial in which patients with acute proximal deep vein thrombosis were randomized to receive either intravenous standard heparin in the hospital or subcutaneous low-molecular-weight heparin administered primarily at home. Treatment in the home has the potential to substanti...

objective: to determine the incidence of deep vein thrombosis (dvt) in patients undergoing spinal surgeries receiving prophylactic doses of deltaparin in a single center in central iran. method: this cross-sectional study was conducted in shariatee hospital of isfahan during a 12-month period. we included all the patients undergoing elective spinal surgeries in our center during the study perio...

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug effect from unfractionated or low-molecular weight heparin that results in and potentially catastrophic thrombosis. HIT occurs due to the development of platelet-activating antibodies against multimolecular complexes platelet factor 4 (PF4) heparin. Given frequency use among hospitalized patients, calculation 4Ts Score re...

OBJECTIVE To evaluate the efficacy and safety of two subcutaneous prophylactic regimens for postoperative deep vein thrombosis after total hip replacement. DESIGN Prospective open randomised multicentre trial. SETTING 28 European departments of orthopaedic surgery. INTERVENTION All patients had bilateral phlebography 10 days after surgery. 31 patients receiving low molecular weight hepari...

CONTEXT When unfractionated heparin is used to treat acute venous thromboembolism, it is usually administered by intravenous infusion with coagulation monitoring, which requires hospitalization. However, subcutaneous administration of fixed-dose, weight-adjusted, unfractionated heparin may be suitable for inpatient and outpatient treatment of venous thromboembolism. OBJECTIVE To determine if ...

BACKGROUND Low-molecular-weight heparin is known to be safe and effective for the initial treatment of patients with proximal deep-vein thrombosis. However, its application to pulmonary embolism or previous episodes of thromboembolism has not been studied. METHODS We randomly assigned 1021 patients with symptomatic venous thromboembolism to fixed-dose, subcutaneous low-molecular-weight hepari...

Background—In the EPILOG trial (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade), abciximab administered with weight-adjusted heparin diminished the risk of ischemic complications within 30 days by 56% among patients undergoing percutaneous coronary revascularization, without increased bleeding complications. Methods and Results—A prospective economic assessm...

Background—In the EPILOG trial (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade), abciximab administered with weight-adjusted heparin diminished the risk of ischemic complications within 30 days by 56% among patients undergoing percutaneous coronary revascularization, without increased bleeding complications. Methods and Results—A prospective economic assessm...